ALK and non-small cell lung carcinoma: Lorlatinib, a third-generation ALK inhibitor, was approved by the US food and drug administration (FDA) as an orphan drug for NSCLC in 2015 and as the second- or third-line treatment for ALK-p advanced NSCLC in 2018 [27].